Predicting response to anti-CD20 therapy in DLBCL patients
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Nov 26, 2013
Grant Date -
Feb 14, 2013
app pub date -
Aug 8, 2011
filing date -
Aug 8, 2011
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
This invention provides methods, compositions, and kits relating to biomarkers whose expression levels are correlated with diffuse large B-cell lymphoma (DLCBL) patients' response to treatment with a CD20 antagonist, such as a CD20 antibody, exemplified by rituximab. The methods, compositions, and kits of the invention can be used to identify DLBCL patients who are likely or not likely, to respond to anti-CD20 treatments.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully